NCT04207255View on ClinicalTrials.gov

Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

March 27, 2020

Primary Completion Date

August 31, 2023

Study Completion Date

July 31, 2024

Conditions
Prostate Cancer
Interventions
DRUG

Opaganib

500mg of Opaganib orally twice a day continuously.

DRUG

Abiraterone

IV as directed by SOC

DRUG

Enzalutamide

IV as directed by SOC

DRUG

Opaganib

250mg of Opaganib orally twice a day continuously.

Trial Locations (2)

20322

Emory University, Atlanta

29425

Medical University of South Carolina, Charleston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Medical University of South Carolina

OTHER

NCT04207255 - Addition of Opaganib to Androgen Antagonists in Patients With mCRPC | Biotech Hunter | Biotech Hunter